ATRX represses alternative lengthening of telomeres

Christine E. Napier, Lily I. Huschtscha, Adam Harvey, Kylie Bower, Jane R. Noble, Eric A Hendrickson, Roger R. Reddel

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

The unlimited proliferation of cancer cells requires a mechanism to prevent telomere shortening. Alternative Lengthening of Telomeres (ALT) is an homologous recombination-mediated mechanism of telomere elongation used in tumors, including osteosarcomas, soft tissue sarcoma subtypes, and glial brain tumors. Mutations in the ATRX/DAXX chromatin remodeling complex have been reported in tumors and cell lines that use the ALT mechanism, suggesting that ATRX may be an ALT repressor. We show here that knockout or knockdown of ATRX in mortal cells or immortal telomerase-positive cells is insufficient to activate ALT. Notably, however, in SV40-transformed mortal fibroblasts ATRX loss results in either a significant increase in the proportion of cell lines activating ALT (instead of telomerase) or in a significant decrease in the time prior to ALT activation. These data indicate that loss of ATRX function cooperates with one or more as-yet unidentified genetic or epigenetic alterations to activate ALT. Moreover, transient ATRX expression in ALT-positive/ATRX-negative cells represses ALT activity. These data provide the first direct, functional evidence that ATRX represses ALT.

Original languageEnglish (US)
Pages (from-to)16543-16558
Number of pages16
JournalOncotarget
Volume6
Issue number18
DOIs
StatePublished - Jan 1 2015

    Fingerprint

Keywords

  • ALT
  • ATRX
  • Immortalization
  • Telomere

Cite this

Napier, C. E., Huschtscha, L. I., Harvey, A., Bower, K., Noble, J. R., Hendrickson, E. A., & Reddel, R. R. (2015). ATRX represses alternative lengthening of telomeres. Oncotarget, 6(18), 16543-16558. https://doi.org/10.18632/oncotarget.3846